Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Update

Seres Therapeutics, Inc. (NASDAQ:MCRB) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 655,113 shares, a decrease of 15.4% from the February 12th total of 774,647 shares. Based on an average daily volume of 58,265 shares, the short-interest ratio is currently 11.2 days. Currently, 7.6% of the shares of the stock are short sold. Currently, 7.6% of the shares of the stock are short sold. Based on an average daily volume of 58,265 shares, the short-interest ratio is currently 11.2 days.

Institutional Trading of Seres Therapeutics

Large investors have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Seres Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after buying an additional 1,160 shares in the last quarter. Invesco Ltd. increased its stake in shares of Seres Therapeutics by 37.5% during the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 3,918 shares during the last quarter. State Street Corp raised its stake in Seres Therapeutics by 14.0% during the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 4,170 shares during the period. Vontobel Holding Ltd. raised its position in shares of Seres Therapeutics by 4.8% in the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 5,157 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Price Performance

NASDAQ MCRB traded up $0.73 on Tuesday, hitting $9.39. 71,271 shares of the company’s stock were exchanged, compared to its average volume of 55,151. The firm’s 50-day moving average price is $12.08 and its two-hundred day moving average price is $15.61. The firm has a market cap of $90.05 million, a price-to-earnings ratio of 14.23 and a beta of 0.31. Seres Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $29.98.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($1.89) EPS for the quarter, topping the consensus estimate of ($2.39) by $0.50. The company had revenue of $0.44 million for the quarter. On average, research analysts predict that Seres Therapeutics will post -0.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MCRB has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Canaccord Genuity Group reiterated a “buy” rating and issued a $22.00 price target on shares of Seres Therapeutics in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Seres Therapeutics has an average rating of “Hold” and an average price target of $14.00.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.